Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists

FASEB Journal

Volumn 28, Issue 1, 2014, Pages 117-130

  Pryce, Gareth ^a,b   Visintin, Cristina ^b,c   Ramagopalan, Sreeram V ^a   Al Izki, Sarah ^a   De Faveri, Lia E ^a   Nuamah, Rosamond A ^a   Mein, Charles A ^a   Montpetit, Alexandre ^e   Hardcastle, Alison J ^d   Kooij, Gijs ^f   De Vries, Helga E ^f   Amor, Sandra ^a,f   Thomas, Sarah A ^g   Ledent, Catherine ^h   Marsicano, Giovanni ⁱ   Lutz, Beat ^j   Thompson, Alan J ^b   Selwood, David L ^c   Giovannoni, Gavin ^a,b   Baker, David ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h FREE UNIVERSITY OF BRUSSELS   (Belgium)

ⁱ UNIVERSITÉ DE BORDEAUX   (France)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

more..

Author keywords

Drug transporters; Experimental autoimmune encephalomyelitis; Genomics; Multidrug resistance transporters; Therapeutics

Indexed keywords

AJULEMIC ACID; BREAST CANCER RESISTANCE PROTEIN; CANNABINOID 1 RECEPTOR AGONIST; MITOXANTRONE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 5; NABIXIMOLS; SAD 448; SPASMOLYTIC AGENT; UNCLASSIFIED DRUG; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANNABIMIMETIC EFFECT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HYPOTHERMIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPASTICITY; TEMPERATURE; YOUNG ADULT; ANIMAL; DRUG POTENTIATION; DRUG TRANSPORTERS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENOMICS; METABOLISM; MULTIDRUG RESISTANCE TRANSPORTERS; THERAPY;

DRUG TRANSPORTERS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENOMICS; MULTIDRUG RESISTANCE TRANSPORTERS; THERAPEUTICS;

ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; RECEPTOR, CANNABINOID, CB1;

EID: 84894520596     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.13-239442     Document Type: Article

References (50)

1. Compston, A., and Coles, A. (2002) Multiple sclerosis. Lancet 259, 1221-1231
2. Baker, D., Pryce, G., Jackson, S. J., Bolton, C., and Giovannoni, G. (2012) The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. Mult. Scler. Rel. Dis. 1, 64-75
3. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54. 161-202.
4. Baker, D., Pryce, G., Croxford, J. L., Brown, P., Pertwee, R. G., Huffman, J. W., and Layward, L. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404, 84-87
5. Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., and Davies, P. Sativex Spasticity Study Group; (2011) A randomized, double-blind, placebo-controlled, parallel- group, enriched-design study of nabiximols* (Sativex(®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18, 1122-1131
6. Zajicek, J. P., Hobart, J. C., Slade, A., Barnes, D., and Mattison, P. G. (2012) MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J. Neurol. Neurosurg. Psychiatr. 83, 1125-1132
7. Corey-Bloom, J., Wolfson, T., Gamst, A., Jin, S., Marcotte, T. D., Bentley, H., and Gouaux, B. (2012) Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. CMAJ 184, 1143-1150
8. Wilkinson, J. D., Whalley, B. J., Baker, D., Pryce, G., Constanti, A., Gibbons, S., and Williamson, E. M. (2003) Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? J. Pharm. Pharmacol. 55, 1687-1694
9. Pryce, G., and Baker, D. (2007) Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br. J. Pharmacol. 150, 519-525
10. Varvel, S. A., Bridgen, D. T., Tao, Q., Thomas, B. F., Martin, B. R., and Lichtman, A. H. (2005). Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice. J. Pharmacol. Exp. Ther. 314, 329-337
11. Huestis, M. A. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 194, 505-515
12. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., and Thompson, A.; UK MS Research Group (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo- controlled trial. Lancet 362, 1517-1526
13. Nielsen, J. B., Crone, C., and Hultborn, H. (2007) The spinal pathophysiology of spasticity from a basic science point of view. Acta Physiol. 189, 171-180
14. Kheder, A., and Nair, K. P. (2012) Spasticity: pathophysiology, evaluation and management. Pract. Neurol. 12, 289-298
15. Rishton, G. M., La Bonte, K., Williams, A. J., Kassam, K., and Kovanov, E. (2006) Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. Curr. Opin. Drug Discov. Devel. 9, 303-313
16. Löscher, W., and Potschka, H. (2005). Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. J. Amer. Soc. Exp. Neuro. Ther. 2, 86-98
17. Hendrikse, N. H., Schinkel, A. H., de Vries, E. G., Fluks, E., Van der Graaf, W. T., Willemsen, A. T., Vaalburg, W., and Franssen, E. J. (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 124, 1413-1418
18. Maresz, K., Pryce, G., Ponomarev, E. D., Marsicano, G., Croxford, J. L., Shriver, L. P., Ledent, C., Cheng, X., Carrier, E. J., Mann, M. K., Giovannoni, G., Pertwee, R. G., Yamamura, T., Buckley, N. E., Hillard, C. J., Lutz, B., Baker, D., and Dittel, B. N. (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat. Med. 13, 492-497
19. Pryce, G., Ahmed, Z., Hankey, D. J., Jackson, S. J., Croxford, J. L., Pocock, J. M., Ledent, C., Petzold, A., Thompson, A. J., Giovannoni, G., Cuzner, M. L., and Baker, D. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126, 2191-2202
20. Zhou, L., Népote, V., Rowley, D. L., Levacher, B., Zvara, A., Santha, M., Mi, Q. S., Simonneau, M., and Donovan, D. M. (2002) Murine peripherin gene sequences direct Cre recombinase expression to peripheral neurons in transgenic mice. FEBS Lett. 523, 68-72
21. Al-Izki, S., Pryce, G., O'Neill, J. K., Butter, C., Giovannoni, G., and Amor, S. (2012) Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult. Scler. Rel. Dis. 1, 29-38
22. Brain, C. T., Dziadulewicz, E. K., and Hart, T. W. (2003) Quinazolinone derivatives and their use as CB agonists. Patent WO03066603, European Patent Office, Munich, Germany; http://worldwide.espacenet.com
23. Adam-Worrall, J., Hill, D. R., and Cotttney, J. (2007). Synergistic combination for the treatment of pain cannabinoid receptor agonist and opioid receptor agonist. Patent WO2007006732, European Patent Office, Munich, Germany; http://worldwide. espacenet.com
24. Dziadulewicz, E. K., Bevan, S. J., Brain, C. T., Coote, P. R., Culshaw, A. J., Davis, A. J., Edwards, L. J., Fisher, A. J., Fox, A. J., Gentry, C., Groarke, A., Hart, T. W., Huber, W., James, I. F., Kesingland, A., La Vecchia, L., Loong, Y., Lyothier, I., McNair, K., O'Farrell, C., Peacock, M., Portmann, R., Schopfer, U., Yaqoob, M., and Zadrobilek, J. (2007) Naphthalen-1-yl-(4- pentyloxynaphthalen- 1-yl)methanone: a potent, orally bioavailable human CB(1)/CB(2) dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J. Med. Chem. 50, 3851-3856
25. Burstein, S. H., Karst, M., Schneider, U., and Zurier, R. B. (2005) Ajulemic acid: a novel cannabinoid produces analgesia without a "high." Life Sci. 75, 1513-1522
26. Lankas, G. R., Cartwright, M. E., and Umbenhauer, D. (1997) P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143, 357-365
27. Pippert, T. R., and Umbenhauer, D. R. (2001) The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene. J. Biochem. Mol. Toxicol. 15, 83-99
28. Langmead, B., and Salzberg, S. Fast gapped-read alignment with Bowtie2. Nat. Methods 9, 357-359
29. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing Subgroup (2009) The sequence alignment/ map (SAM) format and SAMtools. Bioinformatics 25, 2078-2079
30. Kooij, G., van Horssen, J., de Lange, E. C., Reijerkerk, A., van der Pol, S. M., van Het Hof, B., Drexhage, J., Vennegoor, A., Killestein, J., Scheffer, G., Oerlemans, R., Scheper, R., van der Valk, P., Dijkstra, C. D., and de Vries, H. E. (2010) T lymphocytes impair P-glycoprotein function during neuroinflammation. J. Autoimmun. 34, 416-425
31. Carl, S. M., Lindley, D. J., Couraud, P. O., Weksler, B. B., Romero, I., Mowery, S. A., and Knipp, G. T. (2010) ABC and SLC transporter expression and pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol. Pharm. 7, 1057-1068
32. Karst, M. (2007) Comments on "cannabimimetic properties of ajulemic acid". J. Pharmacol. Exp. Ther. 322, 420-421
33. Dyson, A., Peacock, M., Chen, A., Courade, J. P., Yaqoob, M., Groarke, A., Brain, C., Loong, Y., and Fox, A. (2005) Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116, 129-137
34. Hiragata, S., Ogawa, T., Hayashi, Y., Tyagi, P., Seki, S., Nishizawa, O., de Miguel, F., Chancellor, M. B., and Yoshimura, N. (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology 70, 202-208
35. Rawls, S. M., Cabassa, J., Geller, E. B., and Adler, M. W. (2002) CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212-2 [(4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1- naphthalenyl-carbonyl)-6H- pyrrolo[3,2,1ij]quinolin-6-one]- induced hypothermia. J. Pharmacol. Exp. Ther. 301, 963-968
36. Al-Izki, S., Pryce, G., Jackson, S. J., Giovannoni, G., and Baker, D. (2011) Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. Mult. Scler. 17, 939-948
37. Vann, R. E., Cook, C. D., Martin, B. R., and Wiley, J. L. (2007) Cannabimimetic properties of ajulemic acid. J. Pharmacol. Exp. Ther. 320, 678-686
38. Keane, T. M., Goodstadt, L., Danecek, P., White, M. A., Wong, K., Yalcin, B., Heger, A., Agam, A., Slater, G., Goodson, M., Furlotte, N. A., Eskin, E., Nellaker, C., Whitley, H., Cleak, J., Janowitz, D., Hernandez-Pliego, P., Edwards, A., Belgard, T. G., Oliver, P. L., McIntyre, R. E., Bhomra, A., Nicod, J., Gan, X., Yuan, W., van der Weyden, L., Steward, C. A., Bala, S., Stalker, J., Mott, R., Durbin, R., Jackson, I. J., Czechanski, A., Guerra- Assunção, J. A., Donahue, L. R., Reinholdt, L. G., Payseur, B. A., Ponting, C. P., Birney, E., Flint, J., and Adams, D. J. (2011) Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289-294
39. Pawarode, A., Shukla, S., Minderman, H., Fricke, S. M., Pinder, E. M., O'Loughlin, K. L., Ambudkar, S. V., and Baer, M. R. (2007) Differential effects of the immunosuppressive agents cyclosporin A, tacrolimus and sirolimus on drug transport by multidrug resistance proteins. Cancer Chemother. Pharmacol. 60, 179-188
40. Agarwal, N., Pacher, P., Tegeder, I., Amaya, F., Constantin, C. E., Brenner, G. J., Rubino, T., Michalski, C. W., Marsicano, G., Monor, K., Mackie, K., Marian, C., Batkai, S., Parolaro, D., Fischer, M. J., Reeh, P., Kunos, G., Kress, M., Lutz, B., Woolf, C. J., and Kuner, R. (2007) Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 10, 870-879
41. Katona, I., and Freund, T. F. (2006) Multiple functions of endocannabinoid signaling in the brain. Annu. Rev. Neurosci. 35, 529-558
42. Musumeci, G., Grasselli, G., Rossi, S., De Chiara, V., Musella, A., Motta, C., Studer, V., Bernardi, G., Haji, N., Sepman, H., Fresegna, D., Maccarrone, M., Mandolesi, G., and Centonze, D. (2011) Transient receptor potential vanilloid 1 channels modulate the synaptic effects of TNF- and of IL-1 in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 43, 669-677
43. Martin, B. R., Wiley, J. L., Beletskaya, I., Sim-Selley, L. J., Smith, F. L., Dewey, W. L., Cottney, J., Adams, J., Baker, J., Hill, D., Saha, B., Zerkowski, J., Mahadevan, A., and Razdan, R. K. (2006) Pharmacological characterization of novel water-soluble cannabinoids. J. Pharmacol. Exp. Ther. 318, 1230-1239
44. Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., and Arnold, J. C. (2006) The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem. Pharmacol. 71, 1146-1154
45. Bonhomme-Faivre, L., Benyamina, A., Reynaud, M., Farinotti, R., and Abbara, C. (2008) Disposition of Delta(9) tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict. Biol. 13, 295-300
46. Chia, R., Achilli, F., Festing, M. F., and Fisher, E. M. (2005) The origins and uses of mouse outbred stocks. Nat. Genet. 37, 1181-1186
47. Beck, J. A., Lloyd, S., Hafezparast, M., Lennon-Pierce, M., Eppig, J. T., Festing, M. F., and Fisher, E. M. (2000) Genealogies of mouse inbred strains. Nat. Genet. 24, 23-25
48. Omura, S. (2008) Ivermectin: 25 years and still going strong. Int. J. Antimicrob. Agents 31, 91-98
49. Holland, M. L., Lau, D. T., Allen, J. D., and Arnold, J. C. (2007) The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br. J. Pharmacol. 152, 815-824
50. Holland, M. L., Allen, J. D., and Arnold, J. C. (2008) Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur. J. Pharmacol. 591, 128-131